Be Bio Closes $92M Series C Financing, Becomes Clinical Stage Company

Be Biopharma, Inc., a leader in the development of B Cell Medicines, has announced the completion of a $92 million Series C funding round. This round included new investor Nextech, along with existing backers such as ARCH Venture Partners, Atlas Venture, RA Capital Management, and others. As part of this financing, Melissa McCracken, Ph.D., from Nextech, will join the company's Board of Directors.

The funds raised will be primarily used to advance the clinical development of Be Biopharma's leading projects: BE-101 and BE-102. BE-101 is currently undergoing the BeCoMe-9 Phase 1/2 clinical trial aimed at treating individuals with hemophilia B. Meanwhile, BE-102 is poised to enter clinical trials targeting hypophosphatasia, a rare metabolic disorder. Both therapies are based on Be Biopharma's B Cell Medicines platform, designed to offer long-lasting, adjustable, and repeatable treatments that do not require preconditioning of patients.

Joanne Smith-Farrell, Ph.D., CEO of Be Biopharma, expressed confidence in the company's trajectory, emphasizing their readiness to demonstrate clinical proof-of-concept for BE-101 within the year. The CEO also highlighted the potential market impact of BE-102, suggesting it could redefine enzyme replacement therapy for hypophosphatasia by providing a groundbreaking alternative for patients. The recent funding positions Be Biopharma as a robust, multi-program entity in the clinical-stage pipeline, aiming to transform treatment landscapes across various diseases.

Melissa McCracken, Ph.D., from Nextech, expressed enthusiasm about the partnership at this critical juncture for Be Biopharma, acknowledging the promising potential of their programs. She noted that B Cell Medicines could revolutionize treatment methodologies across a range of medical conditions. Nextech looks forward to supporting Be Biopharma's innovative work and its potential to significantly enhance patient care.

B Cell Medicines, the core of Be Biopharma's technology, are a novel form of cellular therapy. These engineered cells are capable of producing therapeutic proteins in a controlled, durable manner, offering a new direction in the development of biologics. B Cell Medicines present opportunities across various therapeutic areas, given their potential to be universally applicable and administered without the need for preconditioning.

Founded in October 2020, Be Biopharma is at the forefront of developing these pioneering therapies, with the mission to improve treatments for patients suffering from genetic diseases, cancer, and other severe health conditions. Supported by a range of investors, including prominent venture capital firms and pharmaceutical partners, Be Biopharma is committed to leveraging the transformative capacities of engineered B cells to innovate and reimagine modern medicine.

In summary, Be Biopharma's recent financial boost is set to propel its groundbreaking work in B Cell Medicines, potentially setting new standards in treatment options for hemophilia B and hypophosphatasia. With a strong funding base and strategic partnerships, the company is well-positioned to lead the charge in this exciting new field of therapeutic development.